Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Aphidicolin glycinate ester; Aphydicolin; Bellinzona; EM 85/061; ICI 137233; NSC 303812

Latest Information Update: 18 Jun 1999

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; National Cancer Institute (USA); Nonindustrial source; Pembury Hospital; SuperGen
  • Class Cytostatic antibiotics
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Herpesvirus infections

Most Recent Events

  • 18 Jun 1999 Discontinued-I for Cancer in Italy (IV-infusion)
  • 18 Jun 1999 Discontinued-I for Cancer in Netherlands (IV-infusion)
  • 18 Jun 1999 Discontinued-I for Cancer in Switzerland (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top